Technical Analysis for AVCT - Avacta Group Plc

Grade Last Price % Change Price Change
grade C 165.0 -6.25% -11.00
AVCT closed down 6.25 percent on Monday, October 26, 2020, on 1.12 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical AVCT trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
Multiple of Ten Bearish Other 0.00%
MACD Bearish Signal Line Cross Bearish -6.25%
20 DMA Support Bullish -6.25%
50 DMA Support Bullish -6.25%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -6.25%
Calm After Storm Range Contraction -6.25%
Multiple of Ten Bullish Other -6.25%
Inside Day Range Contraction -6.25%
Older End-of-Day Gignals for AVCT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 13 hours ago
Fell Below 50 DMA about 16 hours ago
2x Volume Pace about 17 hours ago
1.5x Volume Pace about 17 hours ago
Fell Below Previous Day's Low about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Biotechnology Medicine Branches Of Biology Medical Specialties Immune System Immunology Antibodies

Is AVCT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 215.25
52 Week Low 12.6172
Average Volume 3,112,240
200-Day Moving Average 105.37
50-Day Moving Average 170.22
20-Day Moving Average 173.93
10-Day Moving Average 177.60
Average True Range 15.26
ADX 21.23
+DI 22.80
-DI 18.54
Chandelier Exit (Long, 3 ATRs ) 163.21
Chandelier Exit (Short, 3 ATRs ) 180.97
Upper Bollinger Band 198.93
Lower Bollinger Band 148.92
Percent B (%b) 0.32
BandWidth 28.76
MACD Line 2.76
MACD Signal Line 3.98
MACD Histogram -1.2222
Fundamentals Value
Market Cap 41.69 Billion
Num Shares 253 Million
EPS -11.60
Price-to-Earnings (P/E) Ratio -14.22
Price-to-Sales 48.77
Price-to-Book 6.44
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 185.85
Resistance 3 (R3) 187.53 182.27 182.38
Resistance 2 (R2) 182.27 176.96 181.43 181.22
Resistance 1 (R1) 173.63 173.68 171.00 171.95 180.06
Pivot Point 168.37 168.37 167.05 167.53 168.37
Support 1 (S1) 159.73 163.06 157.10 158.05 149.94
Support 2 (S2) 154.47 159.78 153.63 148.78
Support 3 (S3) 145.83 154.47 147.63
Support 4 (S4) 144.15